CD74 expression and its therapeutic potential in thyroid carcinoma.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• CD74, the invariant chain of major histocompatibility complex class II, acts as a receptor for macrophage migration inhibitory factor (MIF).
• Both CD74 and MIF are implicated in tumor progression and metastasis across various cancers.
• Thyroid cancer progression and associated molecular mechanisms require further investigation.

Purpose of the Study:

• To investigate the expression of CD74 and MIF in different types of thyroid cancer.
• To determine the association between CD74/MIF expression and clinicopathological parameters in thyroid cancer.
• To evaluate the therapeutic potential of targeting CD74 in thyroid cancer.

Main Methods:

• Immunohistochemical staining was performed on papillary thyroid cancer, anaplastic thyroid cancer, normal thyroid tissue, and follicular adenomas to assess CD74 and MIF expression.
• Statistical analysis was used to correlate CD74/MIF expression with clinicopathological features.
• In vitro experiments involved treating thyroid cancer cells with anti-CD74 antibody and recombinant MIF to assess effects on cell behavior and signaling pathways (AKT, AMPK).

Main Results:

• CD74 was expressed in 60% of papillary thyroid cancers and most anaplastic thyroid cancers, while MIF was found in 65% of papillary thyroid cancers.
• Normal thyroid tissue and follicular adenomas were negative for CD74.
• CD74 expression in papillary thyroid cancer correlated with larger tumor size, extrathyroidal invasion, advanced TNM stage, and higher MACIS score.
• Anti-CD74 antibody treatment inhibited thyroid cancer cell growth, migration, invasion, and VEGF secretion, while reducing AKT phosphorylation and activating AMPK.
• Recombinant MIF treatment increased cell invasion.

Conclusions:

• CD74 is overexpressed in thyroid cancers, particularly in advanced stages, and is associated with aggressive tumor characteristics.
• MIF expression is also prevalent in papillary thyroid cancer but lacks association with clinicopathological parameters.
• CD74 represents a potential therapeutic target for thyroid cancer, with anti-CD74 therapy demonstrating inhibitory effects on cancer cell proliferation and metastasis.